---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-408435"
form_type: "8-K"
ticker: "QTTB"
cik: "0001661998"
company_name: "Q32 Bio Inc."
filed_at: "2026-09-30T13:20:10+00:00"
generated_at: "2026-10-12T14:00:16.028723+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Q32 Bio reports positive SIGNAL-AA Part B bempikibart results in alopecia areata

## Summary
- Bempikibart achieved 35.3% mean SALT reduction at Week 36 in mITT; SALT-20 was 40.0% (10/25) mITT and 30.3% (10/33) ITT in severe/very severe alopecia areata.
- SALT 30 and SALT 50 responses each reached 44.0% (11/25) in mITT and 33.3% (11/33) in ITT at Week 36.
- In the 16-week off-drug period, 18 patients entered; SALT-20 was 44%, SALT 30 was 61%, SALT 50 was 50%; maintenance occurred in 100% of 12 Week 36 responders and deepening in 42%.
- Prior oral JAKi responders had 48.3% mean SALT reduction vs 4.8% for non-responders; JAK-naive patients had 44.1%.
- Safety: no serious or Grade 3+ treatment-related AEs; most common TEAE was injection site reaction at 36.3%, all mild; Q32 plans registration-directed AA program in H1 2027.

## SEC filing metadata
- accession: 0001193125-26-408435
- form_type: 8-K
- ticker: QTTB
- cik: 0001661998
- company_name: Q32 Bio Inc.
- filed_at: 2026-09-30T13:20:10+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661998/000119312526408435/0001193125-26-408435-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661998/000119312526408435/d13352d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-408435
- JSON: https://secwatch.observer/filing/0001193125-26-408435.json
- Plain text: https://secwatch.observer/filing/0001193125-26-408435.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.